249 related articles for article (PubMed ID: 25675282)
1. Economic Burden of COPD in the Presence of Comorbidities.
Mannino DM; Higuchi K; Yu TC; Zhou H; Li Y; Tian H; Suh K
Chest; 2015 Jul; 148(1):138-150. PubMed ID: 25675282
[TBL] [Abstract][Full Text] [Related]
2. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
3. The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease.
Hong YD; Onukwugha E; Slejko JF
J Manag Care Spec Pharm; 2020 Oct; 26(10):1353-1362. PubMed ID: 32996389
[TBL] [Abstract][Full Text] [Related]
4. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
5. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
[TBL] [Abstract][Full Text] [Related]
6. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
[TBL] [Abstract][Full Text] [Related]
7. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population.
Schwab P; Dhamane AD; Hopson SD; Moretz C; Annavarapu S; Burslem K; Renda A; Kaila S
Int J Chron Obstruct Pulmon Dis; 2017; 12():735-744. PubMed ID: 28260880
[TBL] [Abstract][Full Text] [Related]
8. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic burden of dyspnea and other COPD symptoms in a managed care setting.
Stephenson JJ; Wertz D; Gu T; Patel J; Dalal AA
Int J Chron Obstruct Pulmon Dis; 2017; 12():1947-1959. PubMed ID: 28740375
[TBL] [Abstract][Full Text] [Related]
10. Utilization due to chronic obstructive pulmonary disease and its predictors: a study using the U.S. National Emergency Department Sample (NEDS).
Singh JA; Yu S
Respir Res; 2016 Jan; 17():1. PubMed ID: 26739476
[TBL] [Abstract][Full Text] [Related]
11. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
12. What is the cost to employers of direct medical care for chronic obstructive pulmonary disease?
Nurmagambetov T; Atherly A; Williams S; Holguin F; Mannino DM; Redd SC
COPD; 2006 Dec; 3(4):203-9. PubMed ID: 17361501
[TBL] [Abstract][Full Text] [Related]
13. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
[TBL] [Abstract][Full Text] [Related]
14. Cost of epilepsy-related health care encounters in the United States.
Borghs S; Beaty S; Parekh W; Kalilani L; Boudiaf N; Loewendorf A
J Manag Care Spec Pharm; 2020 Dec; 26(12):1576-1581. PubMed ID: 33103619
[No Abstract] [Full Text] [Related]
15. Excess economic burden of comorbidities in COPD: a 15-year population-based study.
Chen W; FitzGerald JM; Sin DD; Sadatsafavi M;
Eur Respir J; 2017 Jul; 50(1):. PubMed ID: 28751416
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.
Placzek H; Xu Y; Mu Y; Begelman SM; Fisher M
J Manag Care Spec Pharm; 2015 Dec; 21(12):1106-12. PubMed ID: 26679960
[TBL] [Abstract][Full Text] [Related]
17. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
Dalal AA; Roberts MH; Petersen HV; Blanchette CM; Mapel DW
Int J Chron Obstruct Pulmon Dis; 2010 Dec; 6():13-22. PubMed ID: 21311689
[TBL] [Abstract][Full Text] [Related]
18. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
19. Impact of Comorbidities Among Medicaid Enrollees With Chronic Obstructive Pulmonary Disease, United States, 2009.
Westney G; Foreman MG; Xu J; Henriques King M; Flenaugh E; Rust G
Prev Chronic Dis; 2017 Apr; 14():E31. PubMed ID: 28409741
[TBL] [Abstract][Full Text] [Related]
20. Clinical And Economic Burden Of Eosinophilic COPD In A Large Retrospective US Cohort.
Trudo F; Kallenbach L; Vasey J; Chung Y; Wilk A; Slipski L; O'Brien D; Strange C
Int J Chron Obstruct Pulmon Dis; 2019; 14():2625-2637. PubMed ID: 32063703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]